- Details
- Rashid Sayyid and Zach Klaassen discuss recommendations from the Society for Immunotherapy of Cancer and the International Bladder Cancer Group on clinical trial designs for bladder cancer. They focus on locally advanced and metastatic urothelial carcinoma, emphasizing the need for new treatments and rational trial designs. The panel, comprising 25 multidisciplinary experts, aims to guide late-pha...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss recommendations from the Society for Immunotherapy of Cancer and the International Bladder Cancer Group for muscle-invasive bladder cancer (MIBC) clinical trial design. Published in the Journal of Clinical Oncology with Dr. Ashish Kamat as lead author, these guidelines aim to advance treatment for urothelial carcinoma. The 25-member panel, including a patien...
|
- Details
- Guru Sonpavde and Matt Galsky delve into the CheckMate 901 study and its implications for advanced bladder cancer treatment. Dr. Sonpavde outlines the study's design, focusing on comparing gemcitabine cisplatin with and without nivolumab in cisplatin-eligible patients. He highlights the study's backdrop, noting previous trials and the potential immunogenic superiority of cisplatin. Dr. Galsky pres...
|
- Details
- Alicia Morgans hosts Guru Sonpavde and Bradley McGregor to discuss the DAD trial, which uniquely combines enfortumab vedotin and sacituzumab govitecan, two antibody drug conjugates (ADCs), for advanced urothelial carcinoma. Dr. Sonpavde highlights the distinct mechanisms and non-overlapping toxicities of these drugs. Funded by Gilead, the trial adopts a Phase I BOIN design, starting with lower dos...
|
- Details
- Ashish Kamat and Petros Grivas discuss recent advancements in metastatic bladder cancer treatments from ESMO Congress 2023. Key highlights include the CheckMate-901 and EV-302 trials. Dr. Grivas highlights the CheckMate-901 trial's success with the combination of gemcitabine, cisplatin, and nivolumab, which shows notable improvements in overall survival and progression-free survival with a managea...
|
- Details
- Alicia Morgans speaks with Cora Sternberg about the EV-302 study presented at ESMO 2023. This study marks a significant shift in treating advanced metastatic urothelial cancer, traditionally managed with cisplatin or carboplatin-based chemotherapy. EV-302 introduces a combination of enfortumab vedotin (EV), an antibody-drug conjugate targeting Nectin-4, and pembrolizumab, an anti-PD-1 inhibitor im...
|
- Details
- Shilpa Gupta shares significant insights on the EV-103 study focused on the four-year outcomes of enfortumab vedotin (EV) and pembrolizumab as a frontline treatment for locally advanced or metastatic urothelial cancer patients who are cisplatin ineligible. Dr. Gupta discusses the 73% response rates, median overall survival exceeding two years, and over 41% of patients remaining progression-free af...
|
- Details
- Rafee Talukder discusses his presentation on his research into the effects of MTAP loss on survival rates among advanced urothelial cancer patients undergoing immunotherapy. With the help of an extensive international database, his team found that patients with this MTAP loss exhibited worse observed response rates and a trend toward poorer progression-free survival. In addition, the conversation...
|
- Details
- Alicia Morgans speaks with Jonathan Rosenberg about the approval of the combination of Enfortumab vedotin (EV) and Pembrolizumab for urothelial carcinoma treatment. Dr. Rosenberg notes the impressive response rates (64.5%) from the combination, as compared to EV monotherapy (45%), and highlights the promising survival rates, which significantly exceed expectations for a cisplatin-eligible populati...
|
- Details
- Leslie Ballas, Jason Efstathiou, and Alexandre Zlotta discuss the study Radical Cystectomy Versus Trimodality Therapy for Muscle-Invasive Bladder Cancer: A Multi-Institutional Propensity Score Matched and Weighted Analysis'. The research suggests TMT is as effective as radical cystectomy, exhibiting no significant disparity in five-year survival rates. This implies TMT could be a valuable alternat...
|
